HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Auranofin therapy for juvenile rheumatoid arthritis: results of the five-year open label extension trial.

Abstract
Eighty-eight children with juvenile rheumatoid arthritis (JRA) who completed a double blind, randomized placebo controlled trial of oral gold were entered into an open label extension phase during which they received auranofin (AF) at a dosage of 0.15-0.2 mg/kg/day (9 mg/day maximum). Eleven (12.5%) patients completed 5 years of AF therapy; 77 (87.5%) did not. Fifteen (17%) of the 88 were in disease remission at the final visit. Mean duration of therapy for those who discontinued was 646 days. Parental/patient decision and insufficient therapeutic effect were the 2 most frequent reasons for early termination, followed by adverse effects. Though relatively well tolerated, AF provides adequate longterm management for only a small percentage of patients with JRA.
AuthorsE H Giannini, K S Barron, C H Spencer, D A Person, J Baum, B H Bernstein, D W Kredich, J C Jacobs, L S Zemel, D Gibbas
JournalThe Journal of rheumatology (J Rheumatol) Vol. 18 Issue 8 Pg. 1240-2 (Aug 1991) ISSN: 0315-162X [Print] Canada
PMID1941832 (Publication Type: Clinical Trial, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
Chemical References
  • Auranofin
  • Gold
Topics
  • Administration, Oral
  • Arthritis, Juvenile (drug therapy)
  • Auranofin (therapeutic use)
  • Child
  • Dose-Response Relationship, Drug
  • Double-Blind Method
  • Female
  • Gold (administration & dosage, therapeutic use)
  • Humans
  • Male
  • Time Factors

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: